A Randomized, Open-Label and Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Phase 1 Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Azilsartan medoxomil (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Takeda
- 19 Apr 2017 Status changed from recruiting to completed.
- 04 May 2016 Planned number of patients changed from 48 to 64.
- 04 May 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.